Canagliflozin, a Sodium–glucose cotransporter-2 (SGLT2) inhibitor, attenuates pancreatic fibrosis in chronic pancreatitis through the AMPK–OPG–CTGF axis

Published: 26 May 2026| Version 2 | DOI: 10.17632/5x48kwxdjg.2
Contributor:
Akihisa Adachi

Description

Canagliflozin attenuates pancreatic fibrosis in chronic pancreatitis mediating through the AMPK–Canagliflozin, a Sodium–glucose cotransporter-2 (SGLT2) inhibitor, attenuates pancreatic fibrosis in chronic pancreatitis through the AMPK–OPG–CTGF axisOPG–CTGF axis

Files

Categories

Chronic Pancreatitis

Licence